GlassScriptPhysician profile
Ruthann A Devera
NPI 1790043289
$4,532.63
in general payments reported to CMS, 2019-2025
38 companies · $495 in 2025
The $495 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $828 · 2021: $796 · 2022: $181 · 2023: $471 · 2024: $672 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.30 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,119.99 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Therapeuticsmd, INC. | $322.73 | 2019-2022 | |
| Aspira Women'S Health INC | $278.13 | 2020-2024 | Ova1 |
| Minerva Surgical, INC | $237.45 | 2019-2023 | |
| Astellas Pharma US INC | $214.97 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $205.76 | 2023-2024 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $183.53 | 2019-2025 | |
| Exeltis, USA INC. | $167.42 | 2020-2025 | Slynd |
| Lupin INC. | $164.54 | 2019-2020 | |
| Sage Therapeutics, LLC | $156.00 | 2024-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $124.04 | 2021-2024 | |
| Myovant Sciences INC. | $122.98 | 2021-2022 | |
| Caldera Medical, INC | $116.18 | 2024 | Desara |
| Allergan, INC. | $116.10 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $107.18 | 2021-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $97.15 | 2023-2025 | Accrufer |
| Horizon Therapeutics Plc | $87.47 | 2019-2020 | |
| Avion Pharmaceuticals | $78.25 | 2019-2023 | Balcoltra |
| Bard Access Systems, INC. | $76.04 | 2019 | |
| Organon LLC | $70.77 | 2021-2023 | Nexplanon |
| Radius Health, INC. | $44.99 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $43.09 | 2020-2021 | |
| Coopersurgical, INC. | $40.45 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Alnylam Pharmaceuticals INC. | $37.55 | 2022 | |
| Mylan Pharmaceuticals INC. | $37.04 | 2019 | |
| Vertical Pharmaceuticals, LLC | $31.22 | 2019 | |
| Becton, Dickinson and Company | $27.60 | 2024 | Arista Ah Flexitip |
| Ascend Therapeutics US, LLC | $26.52 | 2019 | |
| Biogen, INC. | $25.80 | 2023 | |
| Olympus America INC. | $25.11 | 2019 | |
| Hologic Sales and Service, LLC | $24.47 | 2023 | Aptima |
| Supernus Pharmaceuticals, INC. | $23.52 | 2025 | Qelbree |
| Pfizer INC. | $19.10 | 2023 | |
| Amag Pharmaceuticals, INC. | $17.80 | 2019 | |
| Covidien LP | $16.42 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.63 | 2019 | |
| Ethicon US, LLC | $15.24 | 2020 | |
| Duchesnay USA Incorporated | $14.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruthann Devera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.